MYND Life Sciences Announces Diagnostic Division with Formation of Wholly-Owned Subsidiary – MYND Diagnostics Ltd.
Ryan Allway October 7th, 2021 Psychedelics MYND Diagnostics was formed to commercialize proprietary biomarker diagnostic tests for patients suffering from MDD, TRD and other psychiatric disorders. VANCOUVER, BC, Oct. 7, 2021 /CNW/ – MYND Life Sciences Inc. (CSE: MYND) (OTC: MYNDF) (“MYND” or the “Company“) is pleased to announce the formation of its... Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )